SCHEMBL12608390

SCHEMBL12608390

CC1(C)[C@@H]2[C@H]3C(=O)N[C@H](C(=O)C(=O)NCC4CC4)CCCCCCCCC[C@H](N)C(=O)N3C[C@@H]21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8290607 1.00 — —
SCHEMBL8290334 0.91 ANPEP (0.30) —
SCHEMBL12608386 0.88 — —
SCHEMBL8291430 0.88 — —
SCHEMBL8290345 0.88 — —
SCHEMBL12607111 0.86 — —
SCHEMBL8046504 0.85 — —
SCHEMBL16349737 0.85 — —
SCHEMBL12855972 0.84 GAA (0.31) —
SCHEMBL8047549 0.84 GAA (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110150835-A1 Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease SCHERING CORPORATION 2011-06-23 — — US disclosed
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
US-7592419-B2 Macrocyclic inhibitors of hepatitis C virus NS3-serine protease SCHERING CORPORATION (US) 2009-09-22 — — US disclosed
Send feedback